A Rare Case: Treatise on Classical Hodg-kin Lymphoma-Mixed Cellularity Stage 3B with Vincristine-Induced Peripheral Neuropathy

Abstract

Classical Hodgkin lymphoma is a lymphatic system cancer that affects 2-1 cases per 100,000 people annually in developed nations. We report a unique case of vincristine-induced peripheral neuropathy associated with acute pancreatitis in a 16-year-old male patient suffering from classical Hodgkin lymphoma (CHL) with the primary symptom of bilateral cervical lymphadenopathy. However, upon diagnosis, this youngster was found to have cervical lymphoma, which differs from the other symptoms of the disease. Diagnosed in February 2023 with CHL, the patient was stratified based on the Ann Arbor staging of Hodgkin lymphoma guidelines by the European Network for Pediatric Hodgkin Lymphoma (EURONET-PHL). Laboratory and physical examination confirmed the clinical conditions of peripheral neuropathy and acute pancreatitis, which are adverse effects of chemotherapy, which were managed with IV Piperacillin Tazobactam (100 mg/kg) and opioid medications. The European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) developed the standard protocol for the first-line therapy of Hodgkin lymphoma in children. Vincristine-induced neuropathy was treated with Morphine (10 mg orally) and Gabapentin (300 mg) was used to provide analgesia. His chemotherapy involved two cycles of an OEPA regimen, in accordance with guidelines for the treatment of CHL, and improved clinically. This case report is being offered to clinically enlighten people about the early diagnosis, treatment of CHL and adverse effects of the vincristine drug used in chemotherapy in pediatric patients.